Genetic test could spare cancer patients from thyroid removal |

Genetic test could spare cancer patients from thyroid removal

Wesley Venteicher
Justin Merriman | Tribune-Review
Dr. Yuri Nikiforov, director of UPMC’s Division of Molecular and Genomic Pathology, led the scientific team that developed the ThyroSeq genetic test.

UPMC is testing a tool that could help reduce the uncertainty doctors and patients face in deciding whether to remove a thyroid after finding cancer.

A clinical trial launched Feb. 1 is enrolling about 100 patients to test a new gene-sequencing panel called ThyroSeq, according to UPMC. The panel could help distinguish between tumors that are aggressive enough to warrant removing the whole thyroid from tumors that only require partial removal, said Dr. Linwah Yip, the trial’s principal investigator.

Cancer in the ear lobe-sized gland, which sits at the top of the neck and produces needed hormones, is rarely fatal, Yip said. But it is costly, and, with about 50,000 to 60,000 new diagnoses per year, it is one of the few cancers that is becoming more common, she said.

“We are looking at a cancer where most people don’t die, so we really want to offer the most optimal treatment course that will maintain and preserve a decent quality of life,” she said.

The current approach to diagnosing thyroid cancer relies on ultrasound images and examinations of biopsied tissue under microscopes. Pathologists look for unusual numbers of cells, malformed cells and misshapen nuclei to identify cancer and try to figure out how aggressive it is, she said.

Based on the findings, doctors talk with patients about how much of the thyroid to remove. The gland can continue functioning after partial removal. If the whole thing is removed, patients need to take medication each day to replace the lost hormones, which help with metabolism, energy levels, weight and temperature regulation, Yip said.

About half of the time doctors do a partial removal, the cancer remains, requiring a second surgery to remove the whole gland, she said.

ThyroSeq identifies specific genetic mutations in the biopsy that indicate how aggressive the cancer is, she said. Researchers hope that the test will help reduce the rate of follow-up surgeries, reducing the risks of harm that surgeries bring and reducing costs, she said.

“We’re looking to see if this is a good way to help differentiate the type of surgery we offer up front,” she said.

The trial is enrolling people locally. It is scheduled to end in November 2018. A UPMC news release says it is funded by individual donors.

Wes Venteicher is a Tribune-Review staff writer. Reach him at 412-380-5676 or [email protected].

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.